(Q33886630)

29 July 2017

1 reference

title

Implications of the United Kingdom prospective diabetes study for patients with obesity and type 2 diabetes (English)

1 reference

29 July 2017

0 references

1 reference

1 reference

S Genuth

1

1 reference

29 July 2017

1 March 2000

1 reference

29 July 2017

1 reference

29 July 2017

8

1 reference

29 July 2017

2

1 reference

29 July 2017

198-201

1 reference

Duration of Obesity Increases the Incidence of NIDDM

29 July 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Weight change and duration of overweight and obesity in the incidence of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Obesity, diabetes and the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

21 January 2018

Insulin use in NIDDM.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Diabetic retinopathy. A clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

The effects of improved glycemic control on complications in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Supplemented fasting in the treatment of obesity and diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

The prevention and treatment of obesity. Application to type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

End-stage renal disease attributable to diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Lower-extremity amputation in people with diabetes. Epidemiology and prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Relation of glycemic control to diabetic microvascular complications in diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Implications of the Diabetes Control and Complications Trial. American Diabetes Association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Inferences and implications. Do results from the Diabetes Control and Complications Trial apply in NIDDM?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Insulin and atheroma--an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Atherosclerotic vascular disease in middle-aged, insulin-treated, diabetic patients. Association with endogenous insulin secretion capacity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

Implications of the United Kingdom Prospective Diabetes Study. American Diabetes Association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.22

31 March 2020

Identifiers

DOI

10.1038/OBY.2000.22

1 reference

29 July 2017

1 reference

PubMed ID

10757207